Verus Capital Partners LLC Takes $699,000 Position in Scholar Rock Holding Corporation $SRRK

Verus Capital Partners LLC acquired a new position in Scholar Rock Holding Corporation (NASDAQ:SRRK) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 18,770 shares of the company’s stock, valued at approximately $699,000.

Other hedge funds also recently added to or reduced their stakes in the company. Penserra Capital Management LLC purchased a new stake in Scholar Rock during the 3rd quarter worth approximately $56,000. Strs Ohio acquired a new stake in shares of Scholar Rock during the first quarter worth $77,000. Bessemer Group Inc. grew its holdings in shares of Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock valued at $86,000 after buying an additional 2,105 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Scholar Rock in the 2nd quarter valued at $94,000. Finally, AlphaQuest LLC raised its stake in Scholar Rock by 30.1% in the 3rd quarter. AlphaQuest LLC now owns 3,415 shares of the company’s stock worth $127,000 after acquiring an additional 791 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SRRK. JPMorgan Chase & Co. boosted their price target on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Wolfe Research began coverage on shares of Scholar Rock in a report on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective on the stock. BMO Capital Markets reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Finally, HC Wainwright boosted their price objective on Scholar Rock from $44.00 to $58.00 and gave the company a “buy” rating in a report on Monday, January 26th. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $51.14.

Insiders Place Their Bets

In other Scholar Rock news, insider Jing L. Marantz sold 4,157 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider directly owned 126,012 shares of the company’s stock, valued at $5,863,338.36. This trade represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Junlin Ho sold 9,580 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $445,757.40. Following the completion of the transaction, the general counsel directly owned 241,545 shares in the company, valued at $11,239,088.85. This represents a 3.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 336,448 shares of company stock valued at $14,971,883 in the last three months. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Price Performance

NASDAQ:SRRK opened at $47.01 on Tuesday. The stock has a market capitalization of $4.80 billion, a PE ratio of -14.92 and a beta of 0.67. Scholar Rock Holding Corporation has a 52 week low of $22.71 and a 52 week high of $49.82. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock’s 50-day moving average price is $45.20 and its 200-day moving average price is $38.52.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).